Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. Phiri K, et al. Among authors: odsbu i. Curr Med Res Opin. 2021 May;37(5):867-877. doi: 10.1080/03007995.2021.1891035. Epub 2021 Mar 8. Curr Med Res Opin. 2021. PMID: 33591859 Free article.
Recognition and management of children and adolescents with conduct disorder: a real-world data study from four western countries.
Bachmann CJ, Scholle O, Bliddal M, dosReis S, Odsbu I, Skurtveit S, Wesselhoeft R, Vivirito A, Zhang C, Scott S. Bachmann CJ, et al. Among authors: odsbu i. Child Adolesc Psychiatry Ment Health. 2024 Jan 28;18(1):18. doi: 10.1186/s13034-024-00710-6. Child Adolesc Psychiatry Ment Health. 2024. PMID: 38281951 Free PMC article.
Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe.
Fortuny J, von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C, Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S, Schink T, Rascher K, Rasouliyan L, Rothman KJ, Saigi-Morgui N, Schaller M, Smits E, Forstner M; Intravenous Iron Consortium; Bénichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L. Fortuny J, et al. Among authors: odsbu i. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-1457. doi: 10.1002/pds.5319. Epub 2021 Jul 12. Pharmacoepidemiol Drug Saf. 2021. PMID: 34181291 Free PMC article.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Among authors: odsbu i. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
59 results